LT2003008A - Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę - Google Patents

Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę

Info

Publication number
LT2003008A
LT2003008A LT2003008A LT2003008A LT2003008A LT 2003008 A LT2003008 A LT 2003008A LT 2003008 A LT2003008 A LT 2003008A LT 2003008 A LT2003008 A LT 2003008A LT 2003008 A LT2003008 A LT 2003008A
Authority
LT
Lithuania
Prior art keywords
use against
organ fibrosis
against organ
parapox ovis
ovis virus
Prior art date
Application number
LT2003008A
Other languages
English (en)
Other versions
LT5064B (lt
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of LT2003008A publication Critical patent/LT2003008A/lt
Publication of LT5064B publication Critical patent/LT5064B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Šis išradimas yra susijęs su inaktyvuotų pararaupų virusų panaudojimu gamyboje vaistų, skirtų gydyti ligas, kurias žmogaus organizme lydi padidintas kolageno susikaupimas, galintis paveikti vidaus organus, tokius kaip kepenys, ir odą bei ją lydinčias struktūras. Šis išradimas ypatingai yra susijęs su kepenų fibroze ir kepenų ciroze, sukeltas virusinio hepatito arba etanolio vartojimo, o taip pat cistine fibroze.ą
LT2003008A 2000-07-11 2003-02-03 Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę LT5064B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen

Publications (2)

Publication Number Publication Date
LT2003008A true LT2003008A (lt) 2003-07-25
LT5064B LT5064B (lt) 2003-11-25

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003008A LT5064B (lt) 2000-07-11 2003-02-03 Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę

Country Status (30)

Country Link
US (1) US6632647B2 (lt)
EP (1) EP1303302B1 (lt)
JP (1) JP5106736B2 (lt)
CN (1) CN1452496B (lt)
AR (1) AR028800A1 (lt)
AU (2) AU8582701A (lt)
BG (1) BG107447A (lt)
CA (1) CA2415399C (lt)
CZ (1) CZ200372A3 (lt)
DK (1) DK200300014A (lt)
EE (1) EE200300019A (lt)
FI (1) FI20030038A (lt)
GB (1) GB2383752B (lt)
HK (1) HK1054330B (lt)
HR (1) HRP20030097A2 (lt)
HU (1) HU227668B1 (lt)
IL (1) IL153826A0 (lt)
LT (1) LT5064B (lt)
LU (1) LU90996B1 (lt)
LV (1) LV12991B (lt)
MA (1) MA25765A1 (lt)
MX (1) MXPA03000278A (lt)
NO (1) NO20030081D0 (lt)
NZ (1) NZ523535A (lt)
PL (1) PL360839A1 (lt)
RU (1) RU2003104522A (lt)
SE (1) SE0300033L (lt)
SI (1) SI21171A (lt)
SK (1) SK382003A3 (lt)
WO (1) WO2002004019A2 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
AU2002362072A1 (en) 2001-12-07 2003-06-23 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
US11077157B2 (en) 2016-02-16 2021-08-03 Osaka University Medicinal composition for treating fibrosis
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100302994B1 (ko) * 1996-04-15 2001-11-30 안톤 마이어 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
PL360839A1 (en) 2004-09-20
SI21171A (sl) 2003-10-31
CN1452496A (zh) 2003-10-29
CA2415399C (en) 2011-11-08
MA25765A1 (fr) 2003-04-01
RU2003104522A (ru) 2004-06-27
JP5106736B2 (ja) 2012-12-26
HUP0303830A3 (en) 2004-10-28
NZ523535A (en) 2004-12-24
NO20030081L (no) 2003-01-08
CA2415399A1 (en) 2003-01-08
WO2002004019A2 (de) 2002-01-17
CZ200372A3 (cs) 2003-05-14
DK200300014A (da) 2003-03-07
CN1452496B (zh) 2012-10-10
HK1054330A1 (en) 2003-11-28
WO2002004019A3 (de) 2002-08-01
BG107447A (bg) 2003-09-30
HUP0303830A2 (hu) 2004-04-28
IL153826A0 (en) 2003-07-31
GB0302629D0 (en) 2003-03-12
FI20030038A (fi) 2003-03-10
EE200300019A (et) 2004-10-15
SE0300033D0 (sv) 2003-01-10
SE0300033L (sv) 2003-03-10
HK1054330B (zh) 2005-07-15
LU90996B1 (en) 2003-01-08
US20020076418A1 (en) 2002-06-20
MXPA03000278A (es) 2004-04-05
SK382003A3 (en) 2003-07-01
AU2001285827B2 (en) 2006-11-30
US6632647B2 (en) 2003-10-14
HU227668B1 (en) 2011-11-28
GB2383752B (en) 2004-11-24
AR028800A1 (es) 2003-05-21
GB2383752A (en) 2003-07-09
HRP20030097A2 (en) 2005-02-28
NO20030081D0 (no) 2003-01-08
JP2004502741A (ja) 2004-01-29
LT5064B (lt) 2003-11-25
LV12991B (en) 2003-08-20
EP1303302A2 (de) 2003-04-23
AU8582701A (en) 2002-01-21
EP1303302B1 (de) 2009-10-14

Similar Documents

Publication Publication Date Title
BR9710355A (pt) Composição útil para o tratamento de infecções virais em um mamìfero, processo para tratar uma infecção viral em um mamìfero, e, produto medicinal.
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
ATE512976T1 (de) Hemmer des hepatitis-c-virus
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A8 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
ATE500808T1 (de) Onkolytische virustherapie
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
WO2004071426A3 (en) Compounds for the treatment of viral infection
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
BR9707535A (pt) Utilização de uma quantidade farmacologicamente aceitável e terapeuticamente eficaz de um agente leucotrieno b4 (ltb4) e composição farmacêutica.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
ES2165269A1 (es) Derivados de alfa-cetoamidas.
WO1998039426A3 (en) Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
BR0108499A (pt) Agente terapêutico para hepatite c
LT2003008A (lt) Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
JP2006507295A5 (lt)
WO2001097824A3 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
WO2004052905A3 (en) Antiviral nucleoside derivatives
RU2209079C2 (ru) Применение интерферона-альфа 5 в лечении вирусных заболеваний печени

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: AICURIS GMBH & CO. KG, DE

Effective date: 20060824

MM9A Lapsed patents

Effective date: 20140711